



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit: 1627
LADNER, et al.)	Examiner:
Serial No.: 09/893,878)	Confirmation No. 1764
Filed: June 29, 2001)	Washington, D.C.
For: DIRECTED EVOLUTION...)	May 7, 2002
)	Docket No.: LADNER=7M

MAY 08 2002

TECH CENTER 1600/2900

RECEIVED

PRELIMINARY AMENDMENT

Commissioner of Patents
Washington, D.C. 20231

S i r :

IN THE SPECIFICATION

Please replace the paragraph beginning at page 34, lines 24-27, with the following rewritten paragraph:

--BPTI Bovine pancreatic trypsin
 inhibitor, identical to
 aprotinin (Merck Index, entry
 784, p.119 (SEQ ID NO:44))--

Please replace the paragraph on page 38, lines 10-18, with the following rewritten paragraph:


--A candidate IPBD should meet the following criteria:
1) a domain exists that will remain stable under the conditions of its intended use (the domain may comprise the entire protein that will be inserted, e.g. BPTI (SEQ ID NO:44), α -conotoxin GI, or CMTI-III),
2) knowledge of the amino acid sequence is obtainable, and
3) a molecule is obtainable having specific and high affinity for the IPBD, AfM (IPBD).--

Please replace the paragraph on pages 50-51, lines 18-34 and 1-8, with the following rewritten paragraph:

--Polypeptides of this size, however, have disadvantages as binding molecules. According to Olivera et al. (OLIV90a): "Peptides in this size range normally equilibrate among may

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: LADNER, et al
 Serial No.: 09/893,878
 Filed: June 29, 2001
 For: DIRECTED EVOLUTION...



Art Unit: 1627
 Confirmation No.: 1764
 Examiner:
 Washington, D.C.
 Atty.'s Docket: LANDER=7M
 Date: May 7, 2002

RECEIVED
 MAY 08 2002
 TECH CENTER 1600/2900

THE COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231

Sir:
 Transmitted herewith is an ☐ Amendment ☒ Preliminary Amendment, substitute pages 466, 466a, 467-71 in the above-identified application.

- ☐ Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
☐ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
☒ No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)		Small Entity		Other Than a Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For		Present Extra		Rate		Additional Fee
Total	25	Minus	25	0		x 9	\$	x18	\$
Indep.	1	Minus	3	0		x42	\$	x84	\$
First Presentation of Multiple Dependent Claim						140	\$	+280	\$
TOTAL ADDITIONAL CLAIMS FEE							\$	Total	\$

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
 ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
 *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.
 The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col.1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time
 If any extension of time for a response is required applicant requests that this be considered a petition therefor.

☐ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- ☐ First - \$ 55.00
☐ Second - \$200.00
☐ Third - \$460.00
☐ Fourth - \$720.00

Other Than Small Entity

Response Filed Within

- ☐ First - \$ 110.00
☐ Second - \$ 400.00
☐ Third - \$ 920.00
☐ Fourth - \$1440.00

☐ Less fees (\$) already paid for months extension of time on

☐ Please charge my Deposit Account No. 02-4035 in the amount of \$. A duplicate copy of this sheet is attached.

☐ A check in the amount of \$ is attached (check no.).

☐ Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$ is attached.

☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK
 Attorneys for Applicant(s)

Facsimile: (202) 737-3528
 Telephone: (202) 628-5197

By:
 Iver P. Cooper
 Registration No. 28,005

IPC:nmp

G:\BN\F\prou\Ladner7M\cov1.wpd